ECM
CSTL icon

ExodusPoint Capital Management’s Castle Biosciences CSTL Stock Holding History

ExodusPoint Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-21,100
Closed -$1.41M – 2182
2020
Q4 		$1.41M Buy
+21,100
New +$1.14M 0.01% 690

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's CSTL Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Castle Biosciences (CSTL) in Q1 2026: 32,608 shares worth $801K. The stake represents 0.01% of the portfolio and ranks #1055 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in CSTL as recently as Q1 2025.

ExodusPoint Capital Management first reported a position in CSTL in Q2 2020 and has held it in 8 quarters since. The position peaked at $1.55M in Q1 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • ExodusPoint Capital Management held 32,608 shares of Castle Biosciences worth $801K as of Q1 2026.
  • Castle Biosciences was a new ExodusPoint Capital Management position in Q1 2026.
  • Castle Biosciences made up 0.01% of ExodusPoint Capital Management's portfolio in Q1 2026, its #1055 holding.
  • ExodusPoint Capital Management first reported a position in Castle Biosciences in Q2 2020 and has held it in 8 quarters since.
  • ExodusPoint Capital Management's Castle Biosciences position peaked at $1.55M in Q1 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.